UK research partners team up to accelerate MND drug discovery
Drug Discovery World
JUNE 5, 2024
million to fund a new two-year collaborative partnership with King’s College London (KCL) to validate a portfolio of human genetic driven therapeutic targets for motor neuron disease (MND). Historical pipeline data suggests that drug targets with human genetic disease association are twice as likely to lead to approved drugs.
Let's personalize your content